FDA scientists opposed Trump administration move to ease peptide access

Most FDA scientific staff opposed a Health and Human Services plan, backed by Robert F Kennedy Jr, to ease access to unproven wellness peptides, according to six people familiar with it. The policy tells the FDA not to act against specialty pharmacies selling about half a dozen peptides, including BPC-157 and TB-500, which have not passed the agency's safety review.